Want to see HK:6998 full AI Analyst Report?
Genor Biopharma Holdings Limited (6998) Ratios
Genor Biopharma Holdings Limited Ratios
HK:6998's free cash flow for Q2 2026 was $289.10M. For the 2026 fiscal year, HK:6998's free cash flow was decreased by $-7.89M and operating cash flow was $296.99M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.00 | 8.74 | 5.41 | 6.61 | 7.62 |
| Quick Ratio | 0.80 | 4.21 | 5.38 | 6.42 | 7.46 |
| Cash Ratio | 0.48 | 8.67 | 5.08 | 6.10 | 7.03 |
| Solvency Ratio | 0.25 | 4.57 | -2.38 | -2.18 | -2.22 |
| Operating Cash Flow Ratio | 0.20 | -1.00 | -1.85 | -2.22 | -1.99 |
| Short-Term Operating Cash Flow Coverage | 0.42 | 0.00 | 0.00 | 0.00 | -21.00 |
| Net Current Asset Value | $ -551.23M | $ 929.24M | $ 984.95M | $ 1.41B | $ 2.02B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.23 | 0.00 | 0.00 | 0.01 | 0.02 |
| Debt-to-Equity Ratio | 0.39 | 0.00 | 0.01 | 0.02 | 0.02 |
| Debt-to-Capital Ratio | 0.28 | 0.00 | 0.01 | 0.02 | 0.02 |
| Long-Term Debt-to-Capital Ratio | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.71 | 1.12 | 1.22 | 1.17 | 1.15 |
| Debt Service Coverage Ratio | 0.67 | 2.92 | 0.00 | -235.95 | -26.18 |
| Interest Coverage Ratio | 3.86 | 2.54 | 0.00 | -275.28 | -363.72 |
| Debt to Market Cap | 0.32 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest Debt Per Share | 1.00 | 0.55 | 0.01 | 0.06 | 0.12 |
| Net Debt to EBITDA | 0.46 | -1.14 | 2.10 | 2.31 | 2.55 |
| Profitability Margins | |||||
| Gross Profit Margin | 65.18% | 64.61% | 0.00% | 93.83% | 0.00% |
| EBIT Margin | 25.56% | 25.85% | 0.00% | -4579.24% | 0.00% |
| EBITDA Margin | 34.61% | 33.48% | 0.00% | -4242.32% | 0.00% |
| Operating Profit Margin | 25.56% | 25.85% | 0.00% | -4934.75% | 0.00% |
| Pretax Profit Margin | 19.95% | 18.95% | 0.00% | -4597.16% | 0.00% |
| Net Profit Margin | 16.05% | 15.23% | 0.00% | -4584.46% | 0.00% |
| Continuous Operations Profit Margin | 16.05% | 15.23% | 0.00% | -4584.46% | 0.00% |
| Net Income Per EBT | 80.45% | 80.39% | 99.54% | 99.72% | 99.89% |
| EBT Per EBIT | 78.06% | 73.31% | 95.26% | 93.16% | 100.84% |
| Return on Assets (ROA) | 6.56% | 32.61% | -46.61% | -34.53% | -30.23% |
| Return on Equity (ROE) | 11.23% | 36.52% | -56.73% | -40.52% | -34.75% |
| Return on Capital Employed (ROCE) | 15.69% | 61.12% | -58.42% | -42.39% | -33.70% |
| Return on Invested Capital (ROIC) | 10.13% | 49.12% | -58.07% | -42.12% | -33.17% |
| Return on Tangible Assets | 14.60% | 35.36% | -50.45% | -37.42% | -32.15% |
| Earnings Yield | 9.60% | 50.40% | -125.65% | -61.66% | -29.36% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.26 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 2.91 | 11.80 | 0.00 | 0.01 | 0.00 |
| Inventory Turnover | 2.17 | 1.77 | 0.00 | 0.02 | 0.00 |
| Fixed Asset Turnover | 7.96 | 474.39 | 0.00 | 0.08 | 0.00 |
| Asset Turnover | 0.41 | 2.14 | 0.00 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 5.77 | 2.82 | 0.00 | 0.01 | 0.00 |
| Cash Conversion Cycle | 128.32 | 175.57 | 0.00 | -31470.20 | 0.00 |
| Days of Sales Outstanding | 85.75 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 168.04 | 206.51 | 0.00 | 17601.69 | 0.00 |
| Days of Payables Outstanding | 125.48 | 30.94 | 0.00 | 49071.89 | 0.00 |
| Operating Cycle | 253.80 | 206.51 | 0.00 | 17601.69 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.27 | -0.24 | -0.84 | -1.15 | -1.26 |
| Free Cash Flow Per Share | 0.24 | -0.24 | -0.84 | -1.17 | -1.40 |
| Dividend Paid and CapEx Coverage Ratio | 4.80 | -77.79 | -411.14 | -44.59 | -8.74 |
| Capital Expenditure Coverage Ratio | 9.47 | -77.79 | -411.14 | -44.59 | -8.74 |
| Operating Cash Flow Coverage Ratio | 0.30 | -133.90 | -59.42 | -20.21 | -10.87 |
| Operating Cash Flow to Sales Ratio | 0.17 | -0.04 | 0.00 | -36.25 | 0.00 |
| Free Cash Flow Yield | 8.96% | -14.81% | -79.40% | -49.86% | -23.58% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 11.72 | 1.98 | -0.80 | -1.62 | -3.41 |
| Price-to-Sales (P/S) Ratio | 1.67 | 0.30 | 0.00 | 74.35 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.17 | 0.72 | 0.45 | 0.66 | 1.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 11.17 | -6.75 | -1.26 | -2.01 | -4.24 |
| Price-to-Operating Cash Flow Ratio | 9.99 | -6.84 | -1.26 | -2.05 | -4.73 |
| Price-to-Earnings Growth (PEG) Ratio | -0.16 | -0.02 | 0.10 | 0.09 | 0.05 |
| Enterprise Value Multiple | 5.29 | -0.24 | 1.13 | 0.56 | -0.96 |
| Enterprise Value | 4.94B | -223.46M | -621.64M | -375.63M | 804.70M |
| EV to EBITDA | 5.29 | -0.24 | 1.13 | 0.56 | -0.96 |
| EV to Sales | 1.83 | -0.08 | 0.00 | -23.58 | 0.00 |
| EV to Free Cash Flow | 12.23 | 1.81 | 1.46 | 0.64 | -1.16 |
| EV to Operating Cash Flow | 10.94 | 1.83 | 1.46 | 0.65 | -1.29 |
| Tangible Book Value Per Share | 0.13 | 2.05 | 2.13 | 3.26 | 4.69 |
| Shareholders’ Equity Per Share | 2.30 | 2.24 | 2.35 | 3.57 | 5.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.20 | 0.20 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.61 | 5.38 | 0.00 | 0.03 | 0.00 |
| Net Income Per Share | 0.26 | 0.82 | -1.33 | -1.45 | -1.75 |
| Tax Burden | 0.80 | 0.80 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 0.78 | 0.73 | 1.10 | 1.00 | 0.98 |
| Research & Development to Revenue | 0.07 | 0.05 | 0.00 | 36.65 | 0.00 |
| SG&A to Revenue | 0.33 | 0.34 | 0.00 | 8.42 | 0.00 |
| Stock-Based Compensation to Revenue | 0.02 | 0.00 | 0.00 | 3.03 | 0.00 |
| Income Quality | 0.91 | 2.38 | 0.63 | 0.79 | 0.72 |
Currency in CNY